Xiling Shen
YOU?
Author Swipe
View article: Distinct Tumor-Associated Macrophage Signatures Shape the Immune Microenvironment and Patient Prognosis in Renal Cell Carcinoma
Distinct Tumor-Associated Macrophage Signatures Shape the Immune Microenvironment and Patient Prognosis in Renal Cell Carcinoma Open
Renal cell carcinoma (RCC) accounts for 90% of adult renal cancer cases and is characterized by significant heterogeneity within its tumor microenvironment. This study tests the hypothesis that tumor-associated macrophages (TAMs) influence…
View article: Dissecting the epigenome dynamics in human immune cells upon viral and chemical exposure by multimodal single-cell profiling
Dissecting the epigenome dynamics in human immune cells upon viral and chemical exposure by multimodal single-cell profiling Open
Pathogen and chemical exposures lead to profound remodeling of the gene-regulatory landscape across human immune cell populations. Here, we present a single-nucleus chromatin accessibility atlas of human immune cells of individuals exposed…
View article: AI/ML-empowered approaches for predicting T Cell-mediated immunity and beyond
AI/ML-empowered approaches for predicting T Cell-mediated immunity and beyond Open
T cells play a dual role in various physiopathological states, capable of eliminating tumors and infected cells, while also playing a pathogenic role when activated by autoantigens, causing self-tissue damage. The regulation of T cell-pept…
View article: CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer
CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by late diagnosis, early metastasis, and resistance to conventional therapies. A major barrier to effective treatment is its desmoplastic and immun…
View article: Distinct Tumor-Associated Macrophage Signatures Shape the Immune Microenvironment and Patient Prognosis in Renal Cell Carcinoma
Distinct Tumor-Associated Macrophage Signatures Shape the Immune Microenvironment and Patient Prognosis in Renal Cell Carcinoma Open
Renal cell carcinoma (RCC) accounts for 90% of adult renal cancer cases and is characterized by significant heterogeneity within its tumor microenvironment. This study tests the hypothesis that tumor-associated macrophages (TAMs) influence…
View article: Dissecting the Epigenome Dynamics in Human Immune Cells Upon Viral and Chemical Exposure by Multimodal Single-Cell Profiling
Dissecting the Epigenome Dynamics in Human Immune Cells Upon Viral and Chemical Exposure by Multimodal Single-Cell Profiling Open
View article: Cancer Organoids as reliable disease models to drive clinical development of novel therapies
Cancer Organoids as reliable disease models to drive clinical development of novel therapies Open
On September 23–24 (2024) the 6th Workshop IRE on Translational Oncology, titled “Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies,” took place at the IRCCS Regina Elena Cancer Institute in Rome.…
View article: Proteome-wide Mendelian randomization and functional studies uncover therapeutic targets for polycystic ovarian syndrome
Proteome-wide Mendelian randomization and functional studies uncover therapeutic targets for polycystic ovarian syndrome Open
View article: Metastatic colorectal cancer cells upregulate SMLR1 that interacts with tumor-associated macrophages in the liver
Metastatic colorectal cancer cells upregulate SMLR1 that interacts with tumor-associated macrophages in the liver Open
Colorectal cancer liver metastasis (CRLM) is the most common form of metastatic colorectal cancer (CRC), one of the leading causes of cancer deaths. The CRLM microenvironment tends to be more immunosuppressive, making immunotherapy less ef…
View article: Longitudinal intravital imaging of mouse placenta
Longitudinal intravital imaging of mouse placenta Open
Studying placental functions is crucial for understanding pregnancy complications. However, imaging placenta is challenging due to its depth, volume, and motion distortions. In this study, we have developed an implantable placenta window i…
View article: Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models
Chromatin Remodeling in Patient‐Derived Colorectal Cancer Models Open
Patient‐Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient‐derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on drug response remains unclear. …
View article: Tissue-resident memory T cell signatures from single-cell analysis associated with better melanoma prognosis
Tissue-resident memory T cell signatures from single-cell analysis associated with better melanoma prognosis Open
View article: Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations
Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations Open
For over a century, early researchers sought to study biological organisms in a laboratory setting, leading to the generation of both in vitro and in vivo model systems. Patient-derived models of cancer (PDMCs) have more recently come to t…
View article: Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells
Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells Open
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with their use. Therefore…
View article: Epigenetic and transcriptional responses in circulating leukocytes are associated with future decompensation during SARS-CoV-2 infection
Epigenetic and transcriptional responses in circulating leukocytes are associated with future decompensation during SARS-CoV-2 infection Open
View article: Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells
Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer Cells Open
Immune checkpoint inhibitors (ICIs) have demonstrated efficacy and improved survival in a growing number of cancers. Despite their success, ICIs are associated with immune-related adverse events that can interfere with their use. Therefore…
View article: Comprehensive Assessment of the Intrinsic Pancreatic Microbiome
Comprehensive Assessment of the Intrinsic Pancreatic Microbiome Open
Background Small studies in pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) have suggested that intra-pancreatic microbial dysbiosis may drive malignant transformation. We sought to comprehensivel…
View article: Genetics and Environment Distinctively Shape the Human Immune Cell Epigenome
Genetics and Environment Distinctively Shape the Human Immune Cell Epigenome Open
The epigenomic landscape of human immune cells is dynamically shaped by both genetic factors and environmental exposures. However, the relative contributions of these elements are still not fully understood. In this study, we employed sing…
View article: Author Correction: Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion
Author Correction: Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion Open
View article: Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Colorectal cancer is the third most common cancer in the United States and responsible for over 50,000 deaths each year. Therapeutic options for advanced colorectal cancer are limited, and there remains an unmet clinical need to identify n…
View article: Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Supplementary Figures
View article: Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Supplementary Figures
View article: Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Patient demographic are described in supplementary Table 1
View article: Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Colorectal cancer is the third most common cancer in the United States and responsible for over 50,000 deaths each year. Therapeutic options for advanced colorectal cancer are limited, and there remains an unmet clinical need to identify n…
View article: Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer Open
Patient demographic are described in supplementary Table 1
View article: Supplementary Figure 3 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells
Supplementary Figure 3 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells Open
MYC knockdown in CCIC-1 line.
View article: Supplementary Figure 4 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells
Supplementary Figure 4 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells Open
Analysis of CCIC-1 with NOTCH suppression.
View article: Supplementary Figure Legends from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells
Supplementary Figure Legends from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells Open
Contains Supplementary Figure legends for Supplementary Figures 1-6.
View article: Supplementary Movie 1 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells
Supplementary Movie 1 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells Open
3D reconstruction of LGR5+/BMI1+ CCIC-1 asymmetric daughter cell pair
View article: Supplementary Movie 1 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells
Supplementary Movie 1 from NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer–Initiating Cells Open
3D reconstruction of LGR5+/BMI1+ CCIC-1 asymmetric daughter cell pair